SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced that Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics, will participate in a virtual fireside chat at the Evercore ISI 2024 Emerging Biotech Conference on Thursday, February 29, 2024 at 1:05 p.m. ET (10:05 a.m. PT).
A live audio webcast of the fireside chat will be available here and will be available for replay for 90 days following the presentation.
About Switch Therapeutics
Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases - affecting the central nervous system, peripheral nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) Platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for efficient self-delivery and uptake, potency and duration of effect and cell selective RNAi activity. Switch is based in South San Francisco, California. For more information, connect with Switch on LinkedIn or visit www.switchthera.com.
